Updated Phase 2 CAPTIVATE Study Results
“After more than five years, the CAPTIVATE study findings confirm [...]
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease | Presented at the European Hematology Association (EHA) Annual Congress
“These data confirm the observations from our prior clinical readouts [...]
Innovent Biologics Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
Dr. Hui Zhou, Senior Vice President of Innovent, stated: “IBI363, [...]
Positive 6 Month Results from CroíValve’s TANDEM I Study to Treat Tricuspid Regurgitation Presented at New York Valves 2024
Favorable patient outcomes from the TANDEM I first-in-human clinical trial [...]
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Deciphera Pharmaceuticals notes the article titled “Vimseltinib versus placebo for [...]
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a [...]
Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study
The study is designed to assess the clinical utility and [...]
In a Usability Analysis of the ArthroFree Wireless Surgical Camera by Lazurite®, More than 90% of Respondents Agree the Absence of Cables Will Have a Positive Impact on Efficiency and Patient Safety
Medical device and technology company Lazurite® announced that a new [...]
Growth in Use of Proton Therapy for Treating Wider Variety of Conditions | According to New Study Published in Red Journal Reveals Growth
Based on NAPT member survey data and other sources, “Temporal [...]
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries
Sensorion notes This gene therapy for patients suffering from otoferlin [...]